Cat. No. 2007
Chemical Name: (6α,11β,16α,17α)-6,9-Difluoro-11-hydrox
Biological ActivityHigh affinity, selective glucocorticoid receptor agonist (Kd = 0.5 nM). Potently stimulates glucocorticoid receptor-mediated transactivation of gene expression and enhances human eosinophil apoptosis (EC50 = 3.7 nM) in vitro. Inhibits mast cell accumulation in nasal mucosa following topical administration. Lipophilic anti-inflammatory agent with low oral bioavailability. Also potentiates KV1 channels (EC50 = 37 nM).
Licensing InformationSold for research purposes under agreement from GlaxoSmithKline
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Pan et al (2012) Potentiation of the Kv1 family K+ channel by cortisone analogues. ACS Chem.Biol. 7 1641. PMID: 22803826.
Zhang et al (2000) Enhancement of human eosinophil apoptosis by fluticasone propionate, budesonide, and beclomethasone. Eur.J.Pharmacol. 406 325. PMID: 11040338.
Smith and Kreutner (1998) In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneim.-Forsch. 48 956.
Johnson (1995) The anti-inflammatory profile of fluticasone propionate. Allergy 50 11. PMID: 7604948.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Fluticasone propionate from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: Fluticasone propionate, supplier, Selective, high, affinity, glucocorticoid, agonists, Receptors, GlaxoSmithKline, GSK, Tocris Bioscience, Glucocorticoid Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Synthetic retinoid; induces differentiation of stem cellsSI-2 hydrochloride
Steroid receptor coactivator 3 (SRC-3) inhibitorSR 0987
T cell-specific RORγ (RORγt) agonistWAY 252623
Potent LXR agonistSR 9009
December 3 - 7, 2016
San Francisco, CA,